The DOI matches its Crossref record; 140 of the 142 references it cites were found in a registry or an index; 42 of the 101 sources its claims cite were checked for support.
The HPA Axis as Target for Depression
Open accessAbstract
Major depressive disorder (MDD) is a stress-related mental disorder with a lifetime prevalence of 20% and, thus, is one of the most prevalent mental health disorders worldwide. Many studies with a large number of patients support the notion that abnormalities of the hypothalamus-pituitaryadrenal (HPA) axis are crucial for the development of MDD. Therefore, a number of strategies and drugs have been investigated to target different components of the HPA axis: 1) corticotrophinreleasing hormone (CRH) 1 receptor antagonists; 2) vasopressin V1B receptor antagonists, 3) glucocorticoid receptor antagonists, and 4) FKBP5 antagonists. Until now, V1B receptor antagonists and GR antagonists have provided the most promising results. Preclinical data also support antagonists of FKBP5, which seem to be partly responsible for the effects exerted by ketamine. However, as HPA axis alterations occur only in a subset of patients, specific treatment approaches that target only single components of the HPA axis will be effective only in this subset of patients. Companion tests that measure the function of the HPA axis and identify patients with an impaired HPA axis, such as the dexamethasone-corticotrophin-releasing hormone (dex-CRH) test or the molecular dexamethasonesuppression (mDST) test, may match the patient with an effective treatment to enable patient-tailored treatments in terms of a precision medicine approach.
Overview
CoChat Summary
TL;DR
This narrative review argues that HPA axis abnormalities are robustly documented in MDD but occur only in a subset of patients, so treatments targeting single HPA axis components will likely require companion tests for patient selection. It summarizes clinical and preclinical evidence for CRH1, V1B, GR, and FKBP5 antagonists, with V1B antagonists and mifepristone showing the most promising results to date.
Key findings
- MDD has a lifetime prevalence of around 20% and heritability of around 40%; more than 50% of patients fail the first antidepressant prescribed, and about 30% do not respond after several treatment attempts. HPA axis hyperactivity with impaired negative feedback is robustly found in MDD, but not all patients with MDD display HPA axis dysfunction.
- A meta-analysis of over 16 randomized controlled trials and 7 open-label trials with 2972 subjects found a significant difference in efficacy across HPA-axis-targeting medications versus controls; subgroup analyses showed significant differences favoring the GR antagonist mifepristone and V1B receptor antagonists.
- V1B antagonist trials were mixed: SSR149415 at 250 mg, but not 100 mg, led to greater HDRS reduction after 8 weeks, though the trial failed because the escitalopram comparator did not achieve significant HDRS reduction; another trial with 100 mg and 250 mg showed no significant improvement versus placebo; doses above 250 mg significantly reduced cortisol response. ABT-436 showed favorable effects on 2 of 5 MASQ subscales but no significant HDRS effect; TS-121 produced a larger MADRS reduction than placebo after 6 weeks, but the effect was not statistically significant.
- Mifepristone trials (4 double-blind, 2 open-label) suggested significant reduction in psychotic symptoms, the primary outcome, but depressive symptoms were secondary and often not significantly improved versus placebo; a combined analysis of five placebo-controlled trials (cases n = 833, placebo n = 627) found significant psychotic symptom reduction when plasma concentrations were within the therapeutic range (about 1600 ng/ml, equating to around 1200 mg/day). CRH1 antagonist R121919 reduced HDRS but was withdrawn for liver enzyme elevations; CP-316,311 failed to improve depressive symptoms; FKBP5 antagonists SAFit1 and SAFit2 improved stress-coping and neuroendocrine feedback in preclinical models but have not yet been tested in clinical samples.
Methods
- Narrative review; no primary data, systematic search strategy, or meta-analysis conducted by the author is described.
- Synthesizes preclinical and clinical literature on the HPA axis in MDD, including trials of CRH1 receptor antagonists, V1B receptor antagonists, GR antagonists, and FKBP5 antagonists, as well as HPA axis tests such as the DST, dex-CRH test, and molecular DST (mDST).
- Main analysis is a qualitative synthesis of cited studies, reporting selected trial outcomes and meta-analytic findings from prior work.
Limitations
- Stated: HPA axis alterations occur only in a subset of MDD patients; specific HPA-axis-targeting compounds improve depressive symptoms only in a certain proportion of patients; dex-CRH findings are heterogeneous with modest effect sizes; DST sensitivity is only 20–50%; mifepristone trials were often shorter than usual trials and depressive symptoms were secondary outcomes; FKBP5 antagonists have not yet been tested in clinical samples.
- Evident: as a narrative review, it does not describe a systematic search strategy, risk-of-bias assessment, or quantitative synthesis, so conclusions rely on selected cited studies.
- Evident: no primary data or new experimental results are presented.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
34 Valid · 1 Not valid · 29 Not checked · 8 Own results and interpretations
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Numerous clinical and preclinical studies have robustly observed FKBP5/FKBP51 to be a central mediator of childhood adversity and HPA axis dysfunction and other sequelae [108-110].”
§ The HPA Axis as Target for Depression > FKBP5 ANTAGONISTS AND KETAMINE
What the sources say
- Not checked — no full text of the sourcecites [108] Matosin N.; Halldorsdottir T.; Binder E.B.; Understanding the molecular mechanisms underpinning gene by environment interactions in psychiatric disorders: The FKBP5 Model. Biol Psychiatry 2018,83(10),821-830 source
- Not checked — no full text of the sourcecites [109] Martins J.; Yusupov N.; Binder E.B.; Brückl T.M.; Czamara D.; Early adversity as the prototype gene × environment interaction in mental disorders? Pharmacol Biochem Behav 2022,215,173371 source
- Supportedcites [110] Klengel T.; Mehta D.; Anacker C.; Rex-Haffner M.; Pruessner J.C.; Pariante C.M.; Pace T.W.W.; Mercer K.B.; Mayberg H.S.; Bradley B.; Nemeroff C.B.; Holsboer F.; Heim C.M.; Ressler K.J.; Rein T.; Binder E.B.; Allele-specific FKBP5 DNA demethylation mediates gene–childhood trauma interactions. Nat Neurosci 2013,16(1),33-41 source
The Abstract describes FKBP5 as an important regulator of the stress hormone system and reports childhood trauma–dependent changes linked to long-term stress-hormone dysregulation and effects on immune cells and brain areas. It also cites prior human findings on FKBP5 and childhood trauma; the Discussion points to supporting rodent models. Together, these passages support the broad clinical and preclinical characterization in the claim. (LLM, conf=0.87)
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Similar effects were observed in stress-coping models in mice, where FKBP51 was required for stress-coping induced by paroxetine and amitriptyline [136].”
§ The HPA Axis as Target for Depression > FKBP5 ANTAGONISTS AND KETAMINE
What the sources say
- Partly supportedcites [136] Gassen N.C.; Hartmann J.; Zannas A.S.; Kretzschmar A.; Zschocke J.; Maccarrone G.; Hafner K.; Zellner A.; Kollmannsberger L.K.; Wagner K.V.; Mehta D.; Kloiber S.; Turck C.W.; Lucae S.; Chrousos G.P.; Holsboer F.; Binder E.B.; Ising M.; Schmidt M.V.; Rein T.; FKBP51 inhibits GSK3β and augments the effects of distinct psychotropic medications. Mol Psychiatry 2016,21(2),277-289 sourceExperimental — accuracy not yet measured
The section on psychotropic-drug effects in mice says FKBP51 deletion attenuated paroxetine’s effect on depression-like behavior after stress, supporting a role for FKBP51 but not showing that it was strictly required. Our copy does not report amitriptyline-induced stress-coping in mice; amitriptyline appears only in a reference about rat astrocytes. Page numbers are unavailable for the deciding passages. (LLM, conf=0.88)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“SAFit1 and SAFit2 achieved an improvement in stress-coping behavior and neuroendocrine feedback in preclinical models [125, 126].”
§ The HPA Axis as Target for Depression > FKBP5 ANTAGONISTS AND KETAMINE
What the sources say
- Partly supportedcites [125] Kolos J.M.; Voll A.M.; Bauder M.; Hausch F.; FKBP Ligands—Where We Are and Where to Go? Front Pharmacol 2018,9,1425 sourceExperimental — accuracy not yet measured
The “Pharmacological Studies with SAFit2” section reports reduced anxiety-related behavior in mice after SAFit2 treatment, which supports a related preclinical behavioral effect. The “FKBP51” section attributes improved stress-coping behavior to FKBP51-deficient mice, not SAFit treatment. Our copy does not report improved neuroendocrine feedback from either SAFit1 or SAFit2, and describes SAFit1 primarily as a ligand for cellular experiments. (LLM, conf=0.86)
- Not checked — no full text of the sourcecites [126] Gaali S.; Kirschner A.; Cuboni S.; Hartmann J.; Kozany C.; Balsevich G.; Namendorf C.; Fernandez-Vizarra P.; Sippel C.; Zannas A.S.; Draenert R.; Binder E.B.; Almeida O.F.X.; Rühter G.; Uhr M.; Schmidt M.V.; Touma C.; Bracher A.; Hausch F.; Selective inhibitors of the FK506-binding protein 51 by induced fit. Nat Chem Biol 2015,11(1),33-37 source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In fact, sensitivity to identify alterations of the HPA axis could be increased with a successful classification of depressed patients up to 80% [56, 57].”
§ The HPA Axis as Target for Depression > MEASURING THE HPA AXIS ACTIVITY
What the sources say
- Partly supportedcites [56] Bardeleben U.; Holsboer F.; Cortisol response to a combined dexamethasone-human corticotrophin-releasing hormone challenge in patients with depression. J Neuroendocrinol 1989,1(6),485-488 sourceExperimental — accuracy not yet measured
The DEX-CRH test results and Discussion report increased cortisol responses in depressed patients, including those not identified as DST nonsuppressors, supporting improved detection of HPA-axis disturbance. The paper does not report an 80% successful-classification rate or a formal sensitivity estimate. (LLM, conf=0.84)
- Not checked — no full text of the sourcecites [57] Heuser I.; Yassouridis A.; Holsboer F.; The combined dexamethasone/CRH test: A refined laboratory test for psychiatric disorders. J Psychiatr Res 1994,28(4),341-356 source
hedgedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The first test to detect HPA axis alterations was the dexamethasone suppression test (DST), which identifies an insufficient suppression of cortisol following dexamethasone intake [48].”
§ The HPA Axis as Target for Depression > MEASURING THE HPA AXIS ACTIVITY
What the sources say
- Partly supportedcites [48] Carroll B.J.; Martin F.I.R.; Davies B.; Resistance to suppression by dexamethasone of plasma 11-O.H.C.S. levels in severe depressive illness. BMJ 1968,3(5613),285-287 sourceExperimental — accuracy not yet measured
The Subjects and Methods and Results sections describe measuring plasma 11-hydroxycorticosteroids after dexamethasone and finding insufficient suppression in some patients with severe depression. The paper does not establish that the DST was the first test to detect HPA-axis alterations, and it reports 11-hydroxycorticosteroids rather than specifically cortisol. Page numbers are unavailable in our copy. (LLM, conf=0.86)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
41 more claims · 16 with their cited sources checked
Create a free account to see all 72 claims and every source verdict.
- It may state two separate claims as one. 24
- Probably not a substantial claim. 3
Citations
Cites
Protective and Damaging Effects of Stress Mediators
McEwen, B. S. (1998) · New England Journal of Medicine · doi:10.1056/nejm199801153380307 · Cited by 6,733 · cited 1×
“The regulation of these negative feedback loops is crucial for an adaptive stress response [46].”
BackgroundVos, T., Barber, R. M., Bell, B., Bertozzi-Villa, A., Biryukov, S., Bolliger, I., Charlson, F., Davis, A., Degenhardt, L., Dicker, D., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)60692-4 · Cited by 6,414
Physiology and neurobiology of stress and adaptation: central role of the brain
McEwen, B. S. (2007) · Physiological Reviews · doi:10.1152/physrev.00041.2006 · Cited by 5,429 · cited 1×
“FKBP5 is a crucial moderator of the hypothalamic-pituitary-adrenal (HPA) axis function, which is responsible for the fight-or-flight response [27].”
BackgroundStress and the brain: from adaptation to disease
de Kloet, E. R., Joëls, M., & Holsboer, F. (2005) · Nature Reviews Neuroscience · doi:10.1038/nrn1683 · Cited by 4,621 · cited 1×
“A wealth of data report hyperactivity of the HPA axis with impaired sensitivity to negative feedback regulation in MDD [36, 74, 75], particularly in MDD with psychotic features [38, 76, 77].”
BackgroundVale, W., Spiess, J., Rivier, C., & Rivier, J. (1981) · Science · doi:10.1126/science.6267699 · Cited by 3,965
The size and burden of mental disorders and other disorders of the brain in Europe 2010
Wittchen, H. U., Jacobi, F., Rehm, J., Gustavsson, A., Svensson, M., Jönsson, B., Olesen, J., Allgulander, C., Alonso, J., Faravelli, C., et al. (2011) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2011.07.018 · Cited by 3,754 · cited 1×
“These non-sufficient treatment options lead to high rates of early retirement and sick leave [13].”
BackgroundGenetic Epidemiology of Major Depression: Review and Meta-Analysis
Sullivan, P. F., Neale, M. C., & Kendler, K. S. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.10.1552 · Cited by 3,431 · cited 1×
“There is a robust heritability of around 40% [19].”
BackgroundHeim, C., & Nemeroff, C. B. (2001) · Biological Psychiatry · doi:10.1016/s0006-3223(01)01157-x · Cited by 2,791 · cited 1×
“Early-life stress, such as physical, sexual, or emotional childhood trauma, has been generally associated with MDD [23, 24], but the increase of MDD risk is also moderated by genetic variants, for example, by FKBP5 variants [25], encoding the FK 506 binding protein 51 or FKBP51, a co-chaperone of…”
BackgroundOtte, C., Gold, S. M., Penninx, B. W., Pariante, C. M., Etkin, A., Fava, M., Mohr, D. C., & Schatzberg, A. F. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.65 · Cited by 2,269
Carroll, B. J. (1981) · Archives of General Psychiatry · doi:10.1001/archpsyc.1981.01780260017001 · Cited by 2,243 · cited 1×
“An insufficient cortisol suppression was repeatedly found in patients suffering from MDD [49-51].”
Background
Cited by
He, Y., Wang, K., Su, N., Yuan, C., Zhang, N., Hu, X., Fu, Y., & Zhao, F. (2024) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.70099 · Cited by 87
“143 Notably, overactivation of the HPA axis is one of the causes of depression, and gut microbiota dysbiosis can result in the production of different mediators, such as pro-inflammatory cytokines and microbial antigens, which activate the HPA axis across the BBB. 144 Furthermore, gut microbiota dysbiosis increases pe…”
BackgroundInfluentialOn the role of epigenetic modifications of HPA axis in posttraumatic stress disorder and resilience
Khan, Z., Messiri, N. E., Iqbal, E., Hassan, H., Tanweer, M. S., Sadia, S. R., Taj, M., Zaidi, U., Yusuf, K., Syed, N. I., et al. (2025) · Journal of Neurophysiology · doi:10.1152/jn.00345.2024 · Cited by 32
New insights into anti-depression effects of bioactive phytochemicals
Zhao, R., Wang, J., Chung, S. K., & Xu, B. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107566 · Cited by 32
Advances in biosensors for major depressive disorder diagnostic biomarkers
Dong, T., Yu, C., Mao, Q., Han, F., Yang, Z., Yang, Z., Pires, N. M. M., Wei, X., Jing, W., Lin, Q., et al. (2024) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2024.116291 · Cited by 27
The protective role of ginsenoside Rg3 in heart diseases and mental disorders
Shi, L., Luo, J., Wei, X., Xu, X., & Tu, L. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1327033 · Cited by 21
“Various mental disorders have been shown to trigger the activation of the HPA axis (Sur and Lee, 2022b; Emudainohwo et al., 2023; Menke, 2024).”
Background
Metadata
- Authors
- Menke, A.
- Affiliations
- Ludwig-Maximilians-Universität München (DE)
- Corresponding author
- Menke, Andreas
- ORCID
- Menke, Andreas
- Venue
- Current Neuropharmacology
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2024-05
- Volume
- 22
- Issue
- 5
- Pages
- 904-915
- ISSN
- 1570-159X (ISSN-L)
- PMC
- PMC10845091
- OpenAlex
- W4385827296
- Cited by
- 131
- References
- 142
- Citations by year
- 2026: 63 · 2025: 50 · 2024: 18
- FWCI
- 24.35
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- cc-by
- Locations
- Current Neuropharmacology (publishedVersion)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Behavioral Neuroscience › Stress Responses and Cortisol
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuropeptides and Animal Physiology
- Keywords
- major depressive disorder, hypothalamic-pituitary-adrenal axis, HPA axis dysregulation, glucocorticoid receptor antagonist, ketamine, precision medicine, stress-related disorders
- MeSH terms
- Corticotropin-Releasing Hormone, Depression, Major Depressive Disorder, Humans, Hypothalamo-Hypophyseal System, Pituitary-Adrenal System
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The HPA Axis as Target for Depression. https://app.cochat.ai/papers/10.2174/1570159x21666230811141557
- The paper
- Menke, A. (2024). The HPA Axis as Target for Depression. Current Neuropharmacology. https://doi.org/10.2174/1570159x21666230811141557
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.